Dr.Yanagiya from ARCALIS CMC department will present about “mRNA medicine development strategy with optimized mRNA design for effective target protein expression”. 
The RNA Society of Japan – Program (rnaj.org)

To develop effective mRNA vaccines and therapeutics, ARCALIS focuses on improving original mRNA optimizing design method for efficient target protein expression. ARCALIS has also established methods minimizing impurities such as double-stranded RNA (dsRNA), which causes undesired immune response. Our proficient quality controls can evaluate manufactured mRNAs in terms of capping efficiency, the length of poly(A) tail and dsRNA contamination along with protein expression evaluated by in vitro and/or in vivo tests.

Notably, self-amplifying RNA (saRNA), which is a next-generation mRNA therapeutics for a long-lasting protein expression with minimized administration doses, can be efficiently manufactured at ARCALIS. Here, we demonstrate effective mRNA and saRNA manufacturing with high quality for future clinical applications.

Overview
【Location】The University of Tokyo, Yasuda Auditorium
【Date】June 26th (Wed) to 28th (Fri)
【Poster Display】Thursday, June 27th: 1:00PM-2:30PM JST      
【Onsite Poster Board Assignment Number】 P-126
”mRNA therapeutics development strategy with optimized mRNA design for effective target protein expression”